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Edited by Gianni CesareniAbstract Dichloroacetate (DCA) is a promising anticancer and
antidiabetic compound targeting the mitochondrial pyruvate
dehydrogenase kinase (PDHK). This study was undertaken in
order to map the DCA-binding site of PDHK2. Here, we present
evidence that R114, S83, I157 and, to some extent, H115 are
essential for DCA binding. We also show that Y80 and D117
are required for the communication between the DCA-binding
site and active site of PDHK2. These observations provide
important insights into the mechanism of DCA action that
may be useful for the design of new, more potent therapeutic
compounds.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pyruvate dehydrogenase kinase (PDHK) is a dedicated
mitochondrial protein kinase that regulates the enzymatic
activity of pyruvate dehydrogenase multienzyme complex
(PDC) [1] and, thereby, controls the rate of aerobic oxidation
of carbohydrate fuels [2]. In mammals, there are at least four
biochemically and genetically diﬀerent forms of PDHK, i.e.
PDHK1, PDHK2, PDHK3, and PDHK4 [3]. These isoforms
are thought to be responsible for the tissue-speciﬁc regulation
of PDC [4]. In vitro, the kinase activity is regulated by a variety
of metabolites. The substrates of pyruvate dehydrogenase
reaction (pyruvate, NAD+, and CoA) act as PDHK inhibitors
[1,3,4], whereas the products, i.e. NADH and acetyl-CoA, act
as PDHK activators [1,3,4]. Thus, it is generally believed that
under physiological conditions PDHK activity reﬂects the ra-
tio of intramitochondrial concentrations of NAD+/NADHAbbreviations: PDC, pyruvate dehydrogenase complex; PDHK, pyru-
vate dehydrogenase kinase; PDHK1, PDHK2, PDHK3, and PDHK4,
isozymes 1, 2, 3, and 4 of pyruvate dehydrogenase kinase; E1, pyruvate
dehydrogenase component of PDC; E2, dihydrolipoyl acetyltransfer-
ase component of PDC; E3, dihydrolipoamide dehydrogenase com-
ponent of PDC; DCA, dichloroacetate
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doi:10.1016/j.febslet.2007.05.052and CoA/acetyl-CoA, as well as the intramitochondrial con-
centration of pyruvate. This rather complex regulation allows
PDHK to adjust the activity of PDC according to the existing
metabolic demand on a minute-to-minute basis.
Structurally, PDHK is a dimer of two identical subunits
associated in tail-to-tail orientation [5–7]. Each PDHK subunit
consists of two almost equal in size domains: the amino-termi-
nal ‘‘regulatory’’ domain (R domain) and the carboxy-terminal
‘‘kinase’’ domain (K domain) [5,7]. The R domain is assembled
as a four helix bundle and carries the binding sites for pyruvate
and its synthetic analog dichloroacetate (DCA), as well as for
lipoyl-bearing domain (LBD) of PDC [6,7]. The K domain
bears the nucleotide-binding site folded as a mixed a/b sand-
wich and also contributes to the LBD-binding site of the neigh-
boring subunit [5,7]. The active site of PDHK is presumably
located on the interface between the K and R domains [5,7].
Despite the recent progress made in structural characteriza-
tion of PDHK, the molecular mechanisms responsible for the
regulation of kinase activity remain poorly understood. The
available structural data suggest that the allosteric control of
PDHK activity requires communications over distances great-
er than 20 A˚ [6,7]. This makes it diﬃcult to trace the exact sig-
naling pathways involved. In addition, the majority of PDHK
allosteric binding sites have not yet been characterized. Thus,
this study was undertaken in order to map the pyruvate/dichlo-
roacetate-binding site of PDHK2, which is thought to be lo-
cated in the middle of the four helix bundle of the R domain
[7]. Here, for the ﬁrst time, we describe the structural require-
ments that largely deﬁne the aﬃnity of PDHK2 for DCA.2. Materials and methods
2.1. Vector construction and protein expression
Construction of the expression vectors for pyruvate dehydrogenase
component of PDC (E1), dihydrolipoyl acetyltransferase component
of PDC (E2)/dihydrolipoamide dehydrogenase-binding protein of PDC
(E3BP) subcomplex, lipoyl-protein ligase A, and PDHK2 was de-
scribed elsewhere [4,8–10]. Mutagenesis was conducted on previously
described pPDHK2 vector using appropriate oligonucleotide primers
[4]. Reactions were set up using the ExSiteTM site-directed mutagenesis
kit (Stratagene, La Jolla, CA) essentially as recommended by the man-
ufacturer. The presence of mutations and ﬁdelity of the rest of the
DNAs were conﬁrmed by sequencing [11]. General conditions for the
expression of E1, E2/E3BP subcomplex, and PDHK2 were described
previously [4,8,9]. PDHK2 carrying various point mutations were ex-
pressed following the established protocol [4]. Puriﬁcation of E1, E2/
E3BP subcomplex, and of PDHK2 was described elsewhere [8,9].
The protein composition of each protein preparation was evaluated
by SDS–PAGE analysis. Gels were stained with Coomassie R250.
All preparations used in the present study were more than 90% pure.blished by Elsevier B.V. All rights reserved.
Fig. 1. Putative DCA-binding site of PDHK2. Ball-and-stick represen-
tation of DCA-binding site of PDHK2 based on 2bu8 coordinates [7].
Shown are amino acid residues of PDHK2 located within contact
distance from bound DCA. The graphics were generated using
MolScript v2.1.2 and Raster3D v2.7 programs.
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The activity of PDHK2 was determined based on the incorporation
of [32P] phosphate into E1 during 1 min of the reaction as described
previously [4]. All assays received a negative control (minus PDHK2)
to determine the non-speciﬁc incorporation and were conducted in
triplicates. For DCA titration experiments, titrations with acetic acid
were performed as controls. Both DCA and acetate were used as so-
dium salts.
2.3. Tryptophan ﬂuorescence quenching
Steady state ﬂuorescence spectra of PDHK2 were recorded at 20 C
in 50 mM potassium phosphate buﬀer, pH 7.5, containing 0.25 mM
EDTA and 2.0 mM MgCl2, using ISS PC1 photon-counting spectro-
ﬂuorometer equipped with an auto titrator (ISS, Inc., Champaign,
IL) with a band-pass of 1 mm on both the excitation and the emission
monochromators. Samples were excited at 290 nm and emission spec-
tra were recorded from 320 to 420 nm. The titration experiments were
conducted in standard (1 · 1 cm) cells containing protein samples of
the initial volume of 2.0 ml. DCA was added in 2- or 10-ll increments
with constant stirring. PDHK2 and its variants were used in the con-
centration of 1.0 lM. Results were corrected for the non-speciﬁc ﬂuo-
rescence quenching determined in the presence of increasing
concentrations of acetate. Corrected data were transformed and ana-
lyzed using approaches described by Hiromasa and colleagues [12].
2.4. Statistical analysis
The reported parameters represent the means ± S.D. obtained for
three to ﬁve independent determinations. Statistical analysis was per-
formed by an unpaired Student’s t-test. P < 0.05 was considered to
be statistically signiﬁcant.
2.5. Other procedures
SDS–PAGE was carried out according to Laemmli [13]. Protein con-
centrations were determined according to Lowry [14] with bovine ser-
um albumin as a standard.Fig. 2. Enzymatic activities of PDHK2 proteins carrying point
mutations within the putative DCA-binding site. Activity measure-
ments were made as described under Section 2 using 5 lM E1, 20 nM
PDHK2, and 200 lM [c-32P]ATP with speciﬁc activity of 100–
200 cpm/pmol (open bars) or 5 lM E1, 20 nM E2, 20 nM PDHK2,
and 200 lM [c-32P]ATP (closed bars). All measurements were
conducted with negative control (minus PDHK2) in order to determine
the non-speciﬁc incorporation. Shown are the means ± S.D. obtained
for three to ﬁve independent determinations.3. Results and discussion
3.1. Characterization of PDHK2 variants carrying amino acid
substitutions within the putative DCA-binding pocket
DCA is a synthetic analog of pyruvate that inhibits PDHK
activity acting in concert with ADP [3]. This compound shows
a great potential as an oral antidiabetic agent reducing blood
glucose and triglycerides without stimulating insulin secretion
[15]. In addition, DCA very eﬀectively decreases tumor growth
in vitro and in vivo by shifting pyruvate metabolism from gly-
colysis and lactate production to glucose oxidation in the mito-
chondria [16]. Recent structural studies conducted by
Knoechel and colleagues [7] identiﬁed DCA in a small pocket
located in the middle of the four helix bundle of PDHK2 R do-
main. Whether this pocket represents a physiologically sound
DCA-binding site has not been established.
This study was undertaken in order to examine the physio-
logical signiﬁcance of putative DCA-binding pocket identiﬁed
by Knoechel et al. [7] and to establish the molecular mecha-
nism responsible for the recognition of DCA by PDHK2. To-
ward this end, we carried out an alanine-scanning mutagenesis
targeting the amino acid residues lining the DCA-binding
pocket of rat PDHK2, i.e. L53, Y80, S83, I111, R112, R114,
H115, D117, R154, I157, R158, and I161, respectively (Fig. 1).
Mutations were introduced in PDHK2 cDNA using oligo-
nucleotide-directed mutagenesis. Mutagenized cDNAs were
expressed in bacteria essentially as described elsewhere [4].
All cDNAs directed an abundant synthesis of corresponding
protein products. Cellular fractionation revealed that all
PDHK2 variants were expressed in soluble form. The yieldof soluble PDHK-I157A was lower than that of other proteins
due to it tendency to accumulate in inclusion bodies. Puriﬁca-
tion of soluble protein kinases was achieved using immobilized
metal aﬃnity chromatography [4].
The ability of mutant PDHK2 enzymes to phosphorylate
pyruvate dehydrogenase was assessed in the standard phos-
phorylation assay (Fig. 2). With free E1 as a substrate, the
Table 1
Kinetic parameters for inhibition of enzymatic activities of wild-type
and mutant PDHK2 proteins by DCA
PDHK2 IC50 for DCA (mM) Slope factor
Wild-type 2.3 ± 0.3a,b 0.6 ± 0.1
L53A 17.1 ± 1.1 0.6 ± 0.2
Y80A NMc –
S83A NM –
I111A 17.9 ± 1.1 0.6 ± 0.1
R112A 1.2 ± 0.4 0.7 ± 0.2
R114A NM –
H115A 8.4 ± 0.4 0.8 ± 0.1
D117A NM –
R154A 1.7 ± 0.2 0.9 ± 0.1
I157A 0.013 ± 0.002 0.9 ± 0.1
R158A 2.0 ± 0.4 1.0 ± 0.2
I161A 2.7 ± 1.5 0.6 ± 0.2
aKinetic parameters represent the means ± S.D. obtained for three to
ﬁve independent determinations.
bKinase activity was determined by measuring the initial rate of
incorporation of 32P from [c-32P]ATP into E1a subunit of recombinant
E1 as described elsewhere [4]. Prior to the assay, E1, E2, and PDHK2
were reconstituted on ice. The ﬁnal protein concentrations of the re-
combinant proteins in the assay were as follows: E1 at 5 lM; E2 at
20 nM; and PDHK2 at 20 nM. The results were corrected for non-
speciﬁc inhibition determined in the presence of increasing concen-
tration of acetate. Background-corrected kinetic data were ﬁtted and
analyzed using GraFit software (Erithacus Software Ltd., Middlesex,
UK).
cNM, not measurable.
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PDHK2-I111A, PDHK2-R112A, PDHK2-D117A, PDHK2-
R158A, and PDHK2-I161A) displayed the activities compara-
ble to that of the wild-type PDHK2, while the activities of
PDHK2-S83A, PDHK2-R114A, and PDHK2-H115A were
somewhat greater than the activity of wild-type kinase. The
activity of PDHK2-I157A variant was signiﬁcantly reduced.
Similar experiments carried out in the presence of E2 revealed
that all PDHK2 variants retained their sensitivity to the E2
component showing a several-fold increase in kinase activity
in response to the addition of E2 (Fig. 2). Thus, almost all
PDHK2 variants carrying amino acid substitutions within
the putative DCA-binding pocket behaved similar to the
wild-type enzyme suggesting that these mutations did not
cause any functionally signiﬁcant rearrangements in PDHK2
structure. PDHK2-I157A variant showed signiﬁcantly reduced
kinase activity, but responded to the addition of E2 similar to
the wild-type enzyme.
3.2. Eﬀects of amino acid substitutions within the putative DCA-
binding pocket of PDHK2 on the DCA-dependent inhibition
of kinase activity and DCA binding
The eﬀects of DCA on enzymatic activities of mutant
PDHK2 proteins were assayed over a wide range of DCA con-
centrations varied from 0.1 lM to 100 mM (Fig. 3). As sum-
marized in Table 1, a number of mutations, i.e. R112A,
R154A, R158A, and I161A, had little if any eﬀect on the abil-
ity of DCA to inhibit PDHK2 activity, while other mutations
(L53A, I111A, and H115A) caused a rather modest, approxi-
mately 3–8-fold, increase in the apparent IC50 values for
DCA. In contrast, four mutant kinases, i.e. PDHK2-Y80A,
PDHK2-S83A, PDHK2-R114A, and PDHK2-D117A, did
not show an appreciable decrease in activity when DCA inFig. 3. Inhibition of PDHK2 enzymatic activity by DCA. Incremental
decreases in activity with increasing DCA concentration for wild-type
PDHK2, PDHK2-I157A, and PDHK2-R114A are shown by closed
circles, by open squares, and by open triangles, respectively. Activity
measurements were made as described under Section 2 using 5 lM E1,
20 nM E2, 20 nM PDHK2, and 50 lM [c-32P]ATP (speciﬁc activity
100–200 cpm/pmol). The results were corrected for non-speciﬁc inhi-
bition determined in the presence of increasing concentration of
acetate. Background-corrected data were ﬁtted using GraFit software
(Erithacus Software Ltd., Middlesex, UK). Shown are representative
results of three to ﬁve determinations.the assay mixture was varied from 0.1 to 10 mM (Fig. 3 and
Table 1). For these proteins, we could not reach half-inhibition
even at the concentration of DCA as high as 100 mM. Finally,
PDHK2-I157A variant displayed a greatly reduced IC50 value
for DCA (approximately 13 lM). Taken together, these data
strongly suggest that Y80, S83, R114, and D117 along with
I157 are extremely important for the eﬀect of DCA on PDHK2
activity.
In order to get further insight into the molecular mecha-
nisms responsible for recognition of DCA by PDHK2, we
investigated binding of DCA (varied from 0.1 lM to
100 mM) to the wild-type and mutant PDHK2 proteins using
the intrinsic tryptophan ﬂuorescence quenching assay devel-
oped by Hiromasa and colleagues [12] (Fig. 4). In general
agreement with the activity determinations above, R112A,
R154A, R158A, and I161A variants bound DCA similarly or
slightly better than the wild-type kinase, whereas the aﬃnity
of PDHK2-L53A, PDHK2-I111A and of PDHK2-H115A
for DCA was approximately 3–5-fold worse than that of unal-
tered PDHK2 (Table 2). Furthermore, DCA did not cause an
appreciable ﬂuorescence quenching of either PDHK2-S83A or
PDHK2-R114A variant and quenched ﬂuorescence of
PDHK2-I157A at a very low concentrations of the ligand
(EC50 of approximately 3 lM). This outcome is consistent with
the interpretation that weak inhibition of PDHK2-S83A and
PDHK2-R114A activities by DCA reﬂects poor DCA binding
by these mutant kinases, while hypersensitivity of PDHK2-
I157A kinase to DCA is a consequence of its greater aﬃnity
for DCA. In marked contrast with the activity assay, DCA
eﬀectively quenched the intrinsic ﬂuorescence of PDHK2-
D117A and PDHK2-Y80A proteins with EC50 values of
0.63 mM, and 1.98 mM, respectively (Table 2), indicating that
these proteins were capable of DCA binding similarly or
slightly worse than the wild-type kinase. These observations
Fig. 4. Quenching of the intrinsic PDHK2 ﬂuorescence by DCA.
Incremental increases in ﬂuorescence quenching with increasing DCA
concentration for wild-type PDHK2, PDHK2-I157A, and PDHK2-
R114A are shown by closed circles, by open squares, and by open
triangles, respectively. Fluorescence measurements were made as
described under Section 2. Fluorescence quenching data were trans-
formed and analyzed using approaches described by Hiromasa and
colleagues [12]. Shown are representative results of three to ﬁve
determinations.
Table 2
Parameters for DCA binding by the wild-type and mutant PDHK2
proteins
PDHK2 EC50 for DCA (mM) Slope factor
Wild-type 0.42 ± 0.02a 0.79 ± 0.02
L53A 2.09 ± 0.11 0.96 ± 0.05
Y80A 1.98 ± 0.13 0.71 ± 0.03
S83A NMb –
I111A 1.09 ± 0.07 0.81 ± 0.04
R112A 0.31 ± 0.01 0.95 ± 0.02
R114A NM –
H115A 1.46 ± 0.04 1.21 ± 0.03
D117A 0.63 ± 0.02 0.77 ± 0.02
R154A 0.195 ± 0.02 0.98 ± 0.03
I157A 0.0026 ± 0.001 1.02 ± 0.06
R158A 0.12 ± 0.01 1.18 ± 0.04
I161A 0.11 ± 0.02 1.3 ± 0.1
aBinding parameters represent the means ± S.D. obtained for three to
ﬁve independent determinations.
bNM, not measurable.
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in DCA binding.
3.3. Recognition of DCA by PDHK2
Recent crystallographic studies identiﬁed DCA in the pocket
located in the middle of PDHK2 R domain [7]. Based on struc-
tural considerations, the authors proposed that DCA is sand-
wiched between H115 and I157, while its carboxylate group
forms a salt-bridge with R154. In addition, the authors
hypothesized that R158 controls the access of DCA into the
binding pocket [7]. In this study, we examined this model using
alanine scanning mutagenesis. In agreement with the existing
model we found that both H115 and I157 are essential for
DCA binding. In contradiction with this model were our re-
sults showing that neither R154 nor R158 play any signiﬁcantrole in DCA recognition. Instead, S83 and R114 located on the
opposite side of DCA-binding pocket were found to be crucial
for DCA binding. The rational for this discrepancy is currently
unknown.
Of particular interest appears to be the outcome of experi-
ments with PDHK2-Y80A and PDHK2-D117A proteins.
Both kinases bound DCA similarly to the wild-type PDHK2.
However, neither of them displayed an appreciable decrease
in activity in response to the addition of DCA indicating a lack
of communication between the DCA-binding site and active
site. Indeed, in PDHK2 structure these sites are more than
20 A˚ apart and, therefore, there should be some mechanism
whereby the signal is relayed from one site to another. It seems
reasonable to propose that both Y80 and D117 are part of this
signal transduction network connecting the DCA-binding and
active sites of PDHK2.
Thus, although the results of this study provide the ﬁrst evi-
dence that DCA containing pocket identiﬁed by Knoechel and
colleagues [7] represents a physiologically sound DCA-binding
site in PDHK2, it is clear that additional structural studies are
required to further reﬁne our understanding of DCA recogni-
tion and signaling within PDHK2 molecule.
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